Company intelligence / Profile preview

BSP Biological Signal Processing Ltd.

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

BSP has successfully commercialized its HyperQ technology with FDA clearance and CE marking. Clinical studies have demonstrated 30% improvement in sensitivity for detecting coronary artery disease compared to conventional stress ECG, with 96% overall accuracy for intensity-based analysis.[1][6]

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Schiller AG

Beyond the preview

Go deeper on BSP Biological Signal Processing Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSP Biological Signal Processing Ltd..

Explore the full profile